{
    "organizations": [],
    "uuid": "a20844fda1ea0cae6312530cdf265d170e7e3d15",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-redhill-biopharma-plans-to-meet-wi/brief-redhill-biopharma-plans-to-meet-with-fda-in-q2-of-2018-to-discuss-design-for-one-two-pivotal-phase-iii-studies-with-bekinda-12-mg-idUSASC09V84",
    "ord_in_thread": 0,
    "title": "BRIEF-Redhill Biopharma Plans To Meet With FDA In Q2 Of 2018 To Discuss Design For One, Two Pivotal Phase III Studies With Bekinda 12 Mg",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 9 (Reuters) - Redhill Biopharma Ltd:\n* PROVIDES SEMI ANNUAL BUSINESS UPDATE * PLANS TO MEET WITH FDA IN Q2 OF 2018 TO DISCUSS DESIGN FOR ONE OR TWO PIVOTAL PHASE III STUDIES WITH BEKINDA 12 MG FOR IBS-D Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-09T19:19:00.000+03:00",
    "crawled": "2018-04-10T12:54:38.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "redhill",
        "biopharma",
        "ltd",
        "provides",
        "semi",
        "annual",
        "business",
        "update",
        "plan",
        "meet",
        "fda",
        "q2",
        "discus",
        "design",
        "one",
        "two",
        "pivotal",
        "phase",
        "iii",
        "study",
        "bekinda",
        "mg",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}